Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

Noa Dagan; Noam Barda

doi:10.1016/j.cmi.2022.08.017

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

Department of Software and Information Systems Engineering

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1526-1527
Number of pages	2
Journal	Clinical Microbiology and Infection
Volume	28
Issue number	12
Early online date	28 Aug 2022
DOIs	https://doi.org/10.1016/j.cmi.2022.08.017
State	E-pub ahead of print - 28 Aug 2022

Keywords

COVID-19
mRNA vaccines
Observational data
Omicron
Vaccine effectiveness

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cmi.2022.08.017

Cite this

@article{cd3200eddc26466e976720da16b81b2b,

title = "Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant",

keywords = "COVID-19, mRNA vaccines, Observational data, Omicron, Vaccine effectiveness",

author = "Noa Dagan and Noam Barda",

note = "Funding Information: N.D. reports institutional grants to the Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. N.B. reports institutional grants to Sheba Medical Center from Pfizer and Moderna outside the submitted work, with no direct or indirect personal benefits.",

year = "2022",

month = aug,

day = "28",

doi = "10.1016/j.cmi.2022.08.017",

language = "English",

volume = "28",

pages = "1526--1527",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

AU - Dagan, Noa

AU - Barda, Noam

N1 - Funding Information: N.D. reports institutional grants to the Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. N.B. reports institutional grants to Sheba Medical Center from Pfizer and Moderna outside the submitted work, with no direct or indirect personal benefits.

PY - 2022/8/28

Y1 - 2022/8/28

KW - COVID-19

KW - mRNA vaccines

KW - Observational data

KW - Omicron

KW - Vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85139369868&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2022.08.017

DO - 10.1016/j.cmi.2022.08.017

M3 - Comment/debate

C2 - 36038121

AN - SCOPUS:85139369868

SN - 1198-743X

VL - 28

SP - 1526

EP - 1527

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 12

ER -

Effectiveness of first-generation severe acute respiratory syndrome coronavirus 2 mRNA vaccines against the Omicron variant

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this